Home > Resources > Whitepapers > Biotechnology An agent for sustainable socio-economic transformation

Biotechnology An agent for sustainable socio-economic transformation

February 5, 2016

One of the key government departments of India credited with heralding the era of adventure and entrepreneurship in the country’s science – the Department of Biotechnology (DBT) – is entering its youthful years. Thirty, as they say, is the new twenty. In these three eventful decades, DBT’s achievements have been many, in terms of the science it has enabled, the policies it has introduced, as well as the linkages it has established across disciplines and countries. DBT’s many forays into biological sciences education and its societal contributions have also bolstered its position as a formidable science-faring body in the country – as a confident young global icon who looks to the future, armed with a dynamic policy framework, the spirit of adventure and ample room for self-criticism.

Spotlight

Recombine

Recombine is a clinical genetic testing company that facilitates informed medical decisions for patients and providers through innovative products and collaborative research. Our products are built on cutting-edge technologies, and our company is driven by experts in diverse fields who share a vision of a world where the power of personalized genomics is fully harnessed. Recombine’s affordable tests and in-depth genetic counseling services deliver valuable insights to thousands of patients worldwide through our robust network of respected physicians. We leverage the power of big data to achieve new perspectives on the science and delivery of genetics in the realm of fertility and beyond. We are strongly committed to being your partner in genomics as we pursue innovative genetic approaches to improving health outcomes.

OTHER WHITEPAPERS

Gene, Cell, & RNA Therapy Landscape

whitePaper | January 24, 2022

The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization.

Advanced Treatments Gene and Cell Therapy

whitePaper | April 26, 2022

Public Policy Projects (PPP) is a global policy institute offering practical analysis and development across a range of sectors, including health and social care.

The EU Clinical Trials Regulation − What You Need to Know

whitePaper | March 22, 2022

The Clinical Trials Regulation has retained some definitions and refined others. For example the definition of “clinical study”: “Any investigation in relation to humans intended: (a) to discover or verify the clinical, pharmacological or other pharmacodynamic.

State of the Global Biotech Landscape: Where the Opportunities Lie

whitePaper | December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

WHO considerations on Regulatory Convergence of Cell and Gene Therapy Products

whitePaper | December 16, 2021

Use of cells, tissues, and gene therapy products for the treatment of diseases or 72 physiological conditions has become of wide interest due to their potential to address serious 73 unmet medical needs.